Higher immune responses were elicited by mRNA-1083 than high-dose quadrivalent inactivated influenza vaccine for all 4 influenza strains and high-dose quadrivalent inactivated influenza vaccine for 3 ...

A new type of mRNA vaccine is more scalable and adaptable to continuously evolving viruses such as SARS-CoV-2 and H5N1, according to a study by researchers at the University of Pittsburgh School of ...

The BNT162b2 KP.2 vaccine effectively prevents severe COVID-19 outcomes, including hospitalizations and ED or UC visits.

As of May 2023, the WHO recommends the use of a monovalent XBB.1 descendent lineage, such as omicron XBB.1.5, as the vaccine antigen for COVID-19 vaccines. However, BA.2.86 and its descendent lineages ...

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 and spread globally, prompting an international effort to accelerate development of a vaccine. The candidate ...

CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission (EC) has granted marketing authorization for the updated formulation of the ...

Most vaccines are designed to provide immunity against just one pathogen. Vaccines for chicken pox (caused by varicella-zoster virus) were only developed to fight that one disease, for example.

CAMBRIDGE, MA / ACCESS Newswire / August 22, 2025 / Moderna announced today that Health Canada has authorized its updated COVID-19 mRNA vaccine, Spikevax®, targeting the SARS-CoV-2 LP.8.1 variant, for ...